Kolarova, Teodora
Bouvier, Catherine
Article History
Accepted: 12 February 2021
First Online: 22 March 2021
Declarations
:
: Teodora Kolarova has received research funding from Novartis, Advanced Accelerator Applications, Ipsen, ITM Isotopen Technologien München AG, Pfizer, and The Neuroendocrine Tumor (NET) Research Foundation. Catherine Bouvier declares that she has no conflict of interest.
: This article does not contain any studies with human or animal subjects performed by the authors.